This is a news story, published by Yahoo, that relates primarily to Mikael Dolsten news.
For more Mikael Dolsten news, you can click here:
more Mikael Dolsten newsFor more drug discoveries news, you can click here:
more drug discoveries newsFor more news from Yahoo, you can click here:
more news from YahooOtherweb, Inc is a public benefit corporation, dedicated to improving the quality of news people consume. We are non-partisan, junk-free, and ad-free. We use artificial intelligence (AI) to remove junk from your news feed, and allow you to select the best health news, business news, entertainment news, and much more. If you like drug discoveries news, you might also like this article about
Pfizer. We are dedicated to bringing you the highest-quality news, junk-free and ad-free, about your favorite topics. Please come every day to read the latest first COVID vaccine news, heart disease drug Vyndaqel news, drug discoveries news, and other high-quality news about any topic that interests you. We are working hard to create the best news aggregator on the web, and to put you in control of your news feed - whether you choose to read the latest news through our website, our news app, or our daily newsletter - all free!
Tuesday Chief Scientific Officer Mikael DolstenReuters
•77% Informative
Chief Scientific Officer Mikael Dolsten will step down after a more than 15-year career at the drugmaker.
Dolsten, 65 , served as head of Pfizer 's research and development after he joined the company in 2009 .
Pfizer also developed and launched multi-billion dollar products such as heart disease drug Vyndaqel and blood thinner Eliquis.
VR Score
89
Informative language
98
Neutral language
20
Article tone
formal
Language
English
Language complexity
55
Offensive language
not offensive
Hate speech
not hateful
Attention-grabbing headline
not detected
Known propaganda techniques
not detected
Time-value
short-lived
External references
no external sources
Source diversity
no sources
Affiliate links
no affiliate links